ClinicalTrials.gg

Program

Fulvestrant

Also written as “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, “fulvestrant” and “faslodex 500mg”.

Its studies are mostly in Breast Neoplasms · Neoplasms · Carcinoma, Intraductal, Noninfiltrating · Puberty, Precocious · Endometrial Neoplasms, led by 5 companies.

Furthest: phase 4, since May 4, 201525 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca211 open or runningphase 4since May 4, 2015Jul 21, 2003none ahead
Atossa Therapeutics10 open or runningphase 2since Aug 28, 2015Aug 28, 2015none ahead
Criterium11 open or runningphase 2since Sep 3, 2020Sep 3, 2020Dec 31, 2027phase 2 · NCT04567420
Eagle Pharmaceuticals10 open or runningphase 1since Oct 24, 2017Oct 24, 2017none ahead
Fresenius Kabi10 open or runningphase 1since May 30, 2016May 30, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Jul 21, 2003.

  1. Apr 10, 2006Phase 2 study in Breast NeoplasmsAstraZeneca · NCT00313170 · 144 enrolled · Belgium, Canada, Czechia and more
  2. May 18, 2006Phase 1 study in Advanced Breast CancerAstraZeneca · NCT00328120 · 20 enrolled · Japan
  3. May 18, 2006Phase 3 study in Advanced Breast CancerAstraZeneca · NCT00327769 · 234 enrolled · China
  4. Jun 5, 2006Phase 2 study in Endometrial NeoplasmsAstraZeneca · NCT00334295 · 35 enrolled · Germany
  5. Jul 20, 2006Phase 2 study in Breast NeoplasmsAstraZeneca · NCT00357110 · 13 enrolled · Austria, Germany, Norway
  6. Mar 7, 2008Phase 3 study in Advanced Breast CancerAstraZeneca · NCT00635713 · 588 enrolled
  7. Jul 22, 2009Phase 3 study in Breast NeoplasmsAstraZeneca · NCT00944918 · 25 enrolled · Korea, Republic of
  8. Feb 17, 2011Phase 3 study in Breast NeoplasmsAstraZeneca · NCT01300351 · 249 enrolled · China
  9. May 11, 2012Phase 3 study in NeoplasmsAstraZeneca · NCT01602380 · 462 enrolled · United States, Argentina, Brazil and more
  10. May 4, 2015Phase 4 study in Breast NeoplasmsAstraZeneca · NCT02447328 · 83 enrolled · Korea, Republic of
  11. Aug 28, 2015Atossa Therapeutics's first study: phase 2 study in Female Breast CarcinomaNew to Atossa TherapeuticsAtossa Therapeutics · NCT02540330 · 3 enrolled · United States
  12. May 30, 2016Fresenius Kabi's first study: phase 1 study in HealthyNew to Fresenius KabiFresenius Kabi · NCT02795039 · 266 enrolled · Canada
  13. Oct 24, 2017Eagle Pharmaceuticals's first study: phase 1 study in PharmacokineticsNew to Eagle PharmaceuticalsEagle Pharmaceuticals · NCT03324061 · 600 enrolled · United States
  14. Sep 3, 2020Criterium's first study: phase 2 study in Breast NeoplasmsNew to CriteriumCriterium · NCT04567420 · 70 enrolled · United States

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Breast NeoplasmsCriterium · NCT04567420

TargetBeta

ESR1 →read by rule
“Estrogen receptor alpha antagonist; Estrogen receptor degrader”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT04567420Breast Neoplasms · United States2Active, not recruitingCriteriumDec 31, 202770
NCT03324061Pharmacokinetics · United States1CompletedEagle PharmaceuticalsJul 12, 2018600
NCT02795039Healthy · Canada1CompletedFresenius KabiMar 3, 2017266
NCT02540330Female Breast Carcinoma · United States2TerminatedAtossa TherapeuticsAug 13, 20203
NCT02447328Breast Neoplasms · Korea, Republic of4CompletedAstraZenecaMay 6, 201683
NCT01602380Neoplasms · United States, Argentina, Brazil and more3CompletedAstraZenecaApr 11, 2016462
NCT01300351Breast Neoplasms · China3CompletedAstraZenecaMar 2014249
NCT00944918Breast Neoplasms · Korea, Republic of3CompletedAstraZenecaJun 201125
NCT00635713Advanced Breast Cancer3CompletedAstraZeneca588
NCT00357110Breast Neoplasms · Austria, Germany, Norway2CompletedAstraZenecaOct 200813
NCT00334295Endometrial Neoplasms · Germany2CompletedAstraZenecaJan 201135
NCT00328120Advanced Breast Cancer · Japan1CompletedAstraZenecaApr 200620
NCT00327769Advanced Breast Cancer · China3CompletedAstraZeneca234
NCT00313170Breast Neoplasms · Belgium, Canada, Czechia and more2CompletedAstraZenecaJun 13, 2008144
NCT00305448Breast Neoplasms · Japan2CompletedAstraZenecaMar 2008143
NCT00278915Puberty, Precocious · United States, France, Germany and more2CompletedAstraZenecaDec 8, 200930
NCT00274469Breast Neoplasms · United States, Brazil, Bulgaria and more2CompletedAstraZenecaJan 10, 2008205
NCT00272740Breast Neoplasms · Belgium, Switzerland2CompletedAstraZeneca93
NCT00259090Breast Neoplasms · United Kingdom2CompletedAstraZenecaOct 2008120
NCT00256698Breast Neoplasms · Canada, Costa Rica, Finland and more3CompletedAstraZenecaApr 2009514
NCT00241449Breast Neoplasms · United States, Argentina, Australia and more3CompletedAstraZenecaMar 200751
NCT00234403Breast Neoplasms · Spain2CompletedAstraZeneca60
NCT00099437Breast Neoplasms · United States, Belgium, Brazil and more3Active, not recruitingAstraZenecaFeb 27, 2009736
NCT00093002Breast Neoplasms · United States, Austria, Brazil and more2CompletedAstraZeneca179
NCT00065325Breast Neoplasms · United States, Argentina, Belgium and more3CompletedAstraZenecaJun 2006694

How it is read

Names in the registry

  • “Fulvestrant”, 26 entries
  • “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, 2 entries
  • “fulvestrant”, 2 entries
  • “faslodex 500mg”, 1 entry
  • “Fulvestrant injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.